CAJ | 학술논문

目的：评价培美曲塞联合奈达铂治疗晚期肺腺癌的疗效及不良反应。方法：入组32例经病理确诊的晚期肺腺癌患者，给予培美曲塞500mg/m2静滴，第1天；奈达铂80mg/m2静滴，第1天，3周为1个周期，2个周期后评价疗效及不良反应。结果：32例患者中完全缓解（CR）0例，部分缓解（PR）9例，稳定（SD）15例，进展（PD）8例。有效率 RR （CR＋ PR）28．1％。中位生存期11．8个月，1年存活率46．9％。结论：培美曲塞联合奈达铂治疗晚期肺腺癌具有较好的疗效及安全性。
목적：평개배미곡새연합내체박치료만기폐선암적료효급불량반응。방법：입조32례경병리학진적만기폐선암환자，급여배미곡새500mg/m2정적，제1천；내체박80mg/m2정적，제1천，3주위1개주기，2개주기후평개료효급불량반응。결과：32례환자중완전완해（CR）0례，부분완해（PR）9례，은정（SD）15례，진전（PD）8례。유효솔 RR （CR＋ PR）28．1％。중위생존기11．8개월，1년존활솔46．9％。결론：배미곡새연합내체박치료만기폐선암구유교호적료효급안전성。
Objective :To observe the therapeutic effect and toxicity of Pemetrexed combined Nedaplat in the treatment of patients with advanced lung adenocarcinoma .Methods :The 32 patients with pathologically confirmed lung adenocar-cinoma were treated with Pemetrexed 500mg/m2 and Nedaplat 80mg/m2 ,d1 ,ivdrip ,the schedule was repeated every 3 weeks and were evaluated effect after 2 cycles .Results:No patients had complete response (CR) ,9 patients had partial response(PR) ,15 patients had SD ,8 patients had PD ,RR(CR+PR)28 .1% (9/32) .The median survival time was 11 .8 months .The 1-year survival rate was 46 .9% .Conclusion:The pemetrexed combined nedaplat is effective and safe in the treatment of advanced lung adenocarcinoma patients .